Atlas Trials

Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice

Clinical trial NCT03895463 · WITHDRAWN

Trial details

NCT number
NCT03895463
Sponsor
Ipsen
Status
WITHDRAWN
Study type
OBSERVATIONAL
Neuroendocrine Tumors
Start date
2019-08-01
Primary completion
2023-03-26
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.